nVision
nVision’s focus is on women’s health. The company created the first FDA-cleared device for collecting cells from the fallopian tubes, which aimed to enable earlier diagnosis of ovarian cancer. In 2018, nVision was acquired by Boston Scientific.
Healthcare & Biotech
Vision
nVision Medical was a female‑health focused company that pioneered the first FDA-cleared device capable of collecting cellular samples directly from the fallopian tubes—a breakthrough platform designed to enable earlier detection of ovarian cancer. Clinical studies showed the tissue collected by the device correlated strongly with post‑surgical diagnoses, positioning it as a potential tool for identifying malignancies before invasive surgery. In April 2018 Boston Scientific acquired nVision in a deal valued at up to $275 million (including $150 million upfront and $125 million in milestone payments), integrating its diagnostic innovation into a broader women’s oncology portfolio.
Sub-Industries
Medical Diagnostics Sensors
Cancer Diagnostics
Point-of-Care Diagnostics
Healthcare Technology
Medical Device Telehealth
Testimonial
Related Companies
KindBio
The future of organ replacement
Salem, NH, USA
The Embryo Corporation
Scalable embryo gene editing to build the next generation of animal life
Austin, TX, USA
Paterna Biosciecnes
In vitro gematogenesis platform company to address male and female intertility
Salt Lake City, UT, USA
Proton Intelligence
Real-time wearable potassium monitoring
Vancouver, Canada
Origenity
AI-driven cell design, from next-generation genetic medicines to expanding what life can be
San Francisco, USA
Deep Root Biolabs
Plant-powered synthetic biology turning polluted soil into clean ground and reclaimed critical minerals
Baltimore, MD, USA
LightHearted AI
Revolutionizing Point-of-Care Cardiac Detection Using Photonics and AI
London, UK
